Atilla Soran, MD, MPH

In 433 patients undergoing breast surgery, median VAS pain scores declined from 2 on day 1 to 0 by day 30, with severe pain in only 7.4% and opioid use in 2.5%, supporting nonopioid-based analgesic protocols.

Extended drug cessation appears feasible in exceptional responders with HER2+ de novo metastatic breast cancer, with significantly better survival compared with non-exceptional responders.

The etiology and risk factors of breast cancer–related lymphedema (BCRL) are multifactorial and not fully understood.